胆汁淤积性瘙痒发病机制及其治疗研究进展

doi:10.16138/j.1673-6087.2022.01.008

摘要/Abstract

关键词: 胆汁淤积性肝病, 发病机制, 瘙痒原, 治疗

中图分类号:

R575

鲁晓岚, 夏巧云. 胆汁淤积性瘙痒发病机制及其治疗研究进展[J]. 内科理论与实践, 2022, 17(01): 43-47.

参考文献 37

[1]	Trivella J, Levy C. Safety considerations for the management of cholestatic itch[J]. Expert Opin Drug Saf, 2021, 20(8): 915-924. doi: 10.1080/14740338.2021.1915984 URL
[2]	Lieu T, Jayaweera G, Zhao P, et al. The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice[J]. Gastroenterology, 2014, 147(6): 1417-1428. doi: 10.1053/j.gastro.2014.08.042 URL
[3]	Yu H, Zhao T, Liu S, et al. MRGPRX4 is a bile acid receptor for human cholestatic itch[J]. Elife, 2019, 8: e48431. doi: 10.7554/eLife.48431 URL
[4]	Cipriani S, Renga B, D’Amore C, et al. Impaired itching perception in murine models of cholestasis is supported by dysregulation of GPBAR1 signaling[J]. PLoS One, 2015, 10(7): e0129866. doi: 10.1371/journal.pone.0129866 URL
[5]	Yu H, Wangensteen K, Deng T, et al. MRGPRX4 in cholestatic pruritus[J]. Semin Liver Dis, 2021, 41(3): 358-367. doi: 10.1055/s-0041-1730923 URL
[6]	Meixiong J, Vasavda C, Green D, et al. Identification of a bilirubin receptor that may mediate a component of cholestatic itch[J]. Elife, 2019, 8: e44116. doi: 10.7554/eLife.44116 URL
[7]	Patel SP, Vasavda C, Ho B, et al. Cholestatic pruritus: emerging mechanisms and therapeutics[J]. J Am Acad Dermatol, 2019, 81(6): 1371-1378. doi: 10.1016/j.jaad.2019.04.035 URL
[8]	Kittaka H, Uchida K, Fukuta N, et al. Lysophosphatidic acid-induced itch is mediated by signalling of LPA5 receptor, phospholipase D and TRPA1/TRPV1[J]. J Physiol, 2017, 595(8): 2681-2698. doi: 10.1113/JP273961 URL
[9]	Tian B, Wang XL, Huang Y, et al. Peripheral and spinal 5-HT receptors participate in cholestatic itch and antinociception induced by bile duct ligation in rats[J]. Sci Rep, 2016, 6: 36286. doi: 10.1038/srep36286 pmid: 27824106
[10]	Ostadhadi S, Kordjazy N, Haj-Mirzaian A, et al. 5-HT3 receptors antagonists reduce serotonin-induced scratching in mice[J]. Fundam Clin Pharmacol, 2015, 29(3): 310-315. doi: 10.1111/fcp.12112 URL
[11]	Shimizu K, Andoh T, Yoshihisa Y, et al. Histamine released from epidermal keratinocytes plays a role in α-melanocyte-stimulating hormone-induced itching in mice[J]. Am J Pathol, 2015, 185(11): 3003-3010. doi: 10.1016/j.ajpath.2015.07.015 pmid: 26358220
[12]	Andoh T, Suzuki K, Konno M, et al. Pharmacological characterization of a novel mouse model of cholestatic pruritus[J]. Biol Pharm Bull, 2020, 43(7): 1111-1117. doi: 10.1248/bpb.b20-00097 URL
[13]	Bergasa NV. The pruritus of cholestasis: from bile acids to opiate agonists: Relevant after all these years[J]. Med Hypotheses, 2018, 110: 86-89. doi: S0306-9877(17)31112-X pmid: 29317077
[14]	Moniaga CS, Iwamoto S, Kitamura T, et al. Plasma dynorphin a concentration reflects the degree of pruritus in chronic liver disease[J]. Acta Derm Venereol, 2019, 99(4): 442-443. doi: 10.2340/00015555-3139 URL
[15]	Kumada H, Miyakawa H, Muramatsu T, et al. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial[J]. Hepatol Res, 2017, 47(10): 972-982. doi: 10.1111/hepr.12830 URL
[16]	Düll MM, Wolf K, Vetter M, et al. Endogenous opioid levels do not correlate with itch intensity and therapeutic interventions in hepatic pruritus[J]. Front Med (Lausanne), 2021, 8: 641163.
[17]	Wang Q, Hao C, Yao W, et al. Intestinal flora imbalance affects bile acid metabolism and is associated with gallstone formation[J]. BMC Gastroenterol, 2020, 20(1): 59. doi: 10.1186/s12876-020-01195-1 URL
[18]	Kitahata S, Yamamoto Y, Yoshida O, et al. Ileal mucosa-associated microbiota overgrowth associated with pathogenesis of primary biliary cholangitis[J]. Sci Rep, 2021, 11(1): 19705. doi: 10.1038/s41598-021-99314-9 pmid: 34611265
[19]	Rossen NG, Fuentes S, Boonstra K, et al. The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured clostridiales Ⅱ[J]. J Crohns Colitis, 2015, 9(4): 342-348. doi: 10.1093/ecco-jcc/jju023 URL
[20]	Zhan Q, Qi X, Weng R, et al. Alterations of the human gut microbiota in intrahepatic cholestasis of pregnancy[J]. Front Cell Infect Microbiol, 2021, 11: 635680. doi: 10.3389/fcimb.2021.635680 URL
[21]	Ji SG, Juran BD, Mucha S, et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease[J]. Nat Genet, 2017, 49(2): 269-273. doi: 10.1038/ng.3745 URL
[22]	Kim MJ, Kim JY, Kang M, et al. Reduced fecal calprotectin and inflammation in a murine model of atopic dermatitis following probiotic treatment[J]. Int J Mol Sci, 2020, 21(11): 3968. doi: 10.3390/ijms21113968 URL
[23]	Kim IS, Lee SH, Kwon YM, et al. Oral administration of β-glucan and lactobacillus plantarum alleviates atopic dermatitis-like symptoms[J]. J Microbiol Biotechnol, 2019, 29(11): 1693-1706. doi: 10.4014/jmb.1907.07011 URL
[24]	Sanjel B, Shim WS. Recent advances in understanding the molecular mechanisms of cholestatic pruritus[J]. Biochim Biophys Acta Mol Basis Dis, 2020, 1866(12): 165958. doi: 10.1016/j.bbadis.2020.165958 URL
[25]	De Vloo C, Nevens F. Cholestatic pruritus: an update[J]. Acta Gastroenterol Belg, 2019, 82(1): 75-82.
[26]	Ahmadi AR, Chicco M, van den Berge M. Rifampicin for treatment of cholestatic pruritus caused by drug-induced acute liver injury as assessed by the RUCAM classification[J]. Case Reports Hepatol, 2020, 2020: 8872804.
[27]	Webb GJ, Rahman SR, Levy C, et al. Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study[J]. Aliment Pharmacol Ther, 2018, 47(8): 1213-1219. doi: 10.1111/apt.14579 URL
[28]	Murray-Brown FL. Naltrexone for cholestatic itch: a systematic review[J]. BMJ Support Palliat Care, 2021, 11(2): 217-225. doi: 10.1136/bmjspcare-2020-002801 URL
[29]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis[J]. J Hepatol, 2017, 67(1): 145-172. doi: 10.1016/j.jhep.2017.03.022 URL
[30]	Thébaut A, Habes D, Gottrand F, et al. Sertraline as an additional treatment for cholestatic pruritus in children[J]. J Pediatr Gastroenterol Nutr, 2017, 64(3): 431-435. doi: 10.1097/MPG.0000000000001385 URL
[31]	Ovadia C, Lövgren-Sandblom A, Edwards LA, et al. Therapeutic plasma exchange as a novel treatment for severe intrahepatic cholestasis of pregnancy: case series and mechanism of action[J]. J Clin Apher, 2018, 33(6): 638-644. doi: 10.1002/jca.21654 URL
[32]	Chkheidze R, Joseph R, Burner J, et al. Plasma exchange for the management of refractory pruritus of cholestasis: a report of three cases and review of literature[J]. J Clin Apher, 2018, 33(3): 412-418. doi: 10.1002/jca.21573 pmid: 28792089
[33]	Pantzaris ND, Lord T, Sotheran R, et al. Nasobiliary drain diverted through a percutaneous endoscopic gastrostomy tube[J]. Case Rep Gastroenterol, 2021, 15(3): 891-897. doi: 10.1159/000518057 URL
[34]	Hussain AB, Samuel R, Hegade VS, et al. Pruritus secondary to primary biliary cholangitis: a review of the pathophysiology and management with phototherapy[J]. Br J Dermatol, 2019, 181(6): 1138-1145. doi: 10.1111/bjd.17933 pmid: 30920648
[35]	Ziogas IA, Alexopoulos SP, Matsuoka LK, et al. Living vs deceased donor liver transplantation in cholestatic liver disease: an analysis of the OPTN database[J]. Clin Transplant, 2020, 34(10): e14031.
[36]	Hegade VS, Kendrick SF, Dobbins RL, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study[J]. Lancet, 2017, 389(10074): 1114-1123. doi: S0140-6736(17)30319-7 pmid: 28187915
[37]	Al-Dury S, Wahlström A, Wahlin S, et al. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis[J]. Sci Rep, 2018, 8(1): 6658. doi: 10.1038/s41598-018-25214-0 pmid: 29704003

胆汁淤积性瘙痒发病机制及其治疗研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 37

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陆文婷　陈萍　卞薇薇. 冷敷面膜在激光治疗后疼痛护理中的作用[J]. 组织工程与重建外科杂志, 2022, 18(4): 342-.
[2]	陈佳佳　高敏哲　汪立　韩凌华　吴顺军　刘宁飞. 妇科相关肿瘤术后下肢淋巴水肿合并会阴部水肿的综合治疗初探[J]. 组织工程与重建外科杂志, 2022, 18(3): 242-.
[3]	戈成旺　林崴仪　唐枭伟　李磊　宋辉　蔡薇　沈干. 鼻翼退缩的研究进展[J]. 组织工程与重建外科杂志, 2022, 18(3): 284-.
[4]	聂萍　叶启程　王乐之　朱敏　王旭东. 从唇腭裂序列治疗理念的角度探讨医学生人文关怀意识的培养[J]. 组织工程与重建外科杂志, 2022, 18(3): 286-.
[5]	冯秋实. 胆总管结石的微创治疗[J]. 外科理论与实践, 2022, 27(3): 185-188.
[6]	陈胜. 三镜联合微创治疗胆囊结石合并胆总管结石的方案选择[J]. 外科理论与实践, 2022, 27(3): 198-202.
[7]	宣呈杰, 卞冬生, 蒋咏梅, 陈宇菲, 金佳斌, 施咏梅. 营养治疗对减重术后身体成分及静息能量消耗的影响[J]. 外科理论与实践, 2022, 27(3): 244-248.
[8]	许梓枫, 宗雅萍, 陆爱国. 局部进展期结肠癌病人的新辅助治疗[J]. 外科理论与实践, 2022, 27(3): 266-270.
[9]	陈承坤, 郭伯敏, 邓先兆, 伍波, 樊友本. 甲状腺髓样癌的诊治现状[J]. 外科理论与实践, 2022, 27(3): 276-280.
[10]	俞沁圆　王思圆　仲荣洲　李喆　黄国懂　魏雅洁　王斌. 先天性多发手部关节挛缩支具治疗的临床评价[J]. 组织工程与重建外科杂志, 2022, 18(2): 144-.
[11]	许佳　樊佳俊　韩冬　李馨　马燕红. 增生性瘢痕压力治疗的研究进展[J]. 组织工程与重建外科杂志, 2022, 18(2): 176-.
[12]	王小点　崔春晓　夏亮　冯少清　喜雯婧　肖文天　孟心娴　韩承尧　李科　章一新. 远红外线治疗妇科癌症术后下肢淋巴水肿的安全性研究[J]. 组织工程与重建外科杂志, 2022, 18(1): 19-.
[13]	汪立　刘宁飞　陈佳佳　高敏哲　韩凌华. 肢体慢性淋巴水肿CDT治疗后低弹力绷带使用时长对远期疗效的影响[J]. 组织工程与重建外科杂志, 2022, 18(1): 25-.
[14]	黄成　胡学庆. 淋巴水肿治疗的研究进展[J]. 组织工程与重建外科杂志, 2022, 18(1): 38-.
[15]	吴一文　王珊珊　张吕亚　肖喻　林洁　易庆阳　方木平 . 红蓝光照射联合阿达帕林凝胶治疗轻、中度痤疮[J]. 组织工程与重建外科杂志, 2022, 18(1): 74-.